| Literature DB >> 32047773 |
Tie-Duo Kang1, Yan-Long Ren1, Han Zhao1, Shang-Qiu Ning1, Wen-Xian Liu2.
Abstract
BACKGROUND: Fulminant myocarditis is the critical form of myocarditis that is often associated with heart failure, malignant arrhythmia, and circulatory failure. Patients with fulminant myocarditis who end up with severe multiple organic failure and death are not rare. AIM: To analyze the predictors of in-hospital major adverse cardiovascular events (MACE) in patients diagnosed with fulminant myocarditis.Entities:
Keywords: Cardiac arrest; Cardiac shock; Cardiovascular events; Fulminant myocarditis; In-hospital; Risk factors
Year: 2020 PMID: 32047773 PMCID: PMC7000935 DOI: 10.12998/wjcc.v8.i2.255
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
General characteristics, n (%)
| Age (yr) | 31.00 (25.50-48.00) | 26.50 (19.75-34.25) | 0.058 |
| Gender | 0.049 | ||
| Male | 7 (35) | 19 (63.3) | |
| Female | 13 (65) | 11 (36.7) | |
| Precursory symptoms | 19 (95) | 25 (83.3) | 0.381 |
| Fever | 16 (80) | 18 (60) | 0.137 |
| Systolic blood pressure (mmHg) | 87.40 ± 14.91 | 105.77 ± 19.07 | 0.001 |
| Hart rate (beats per minute) | 103.05 ± 22.70 | 86.97 ± 25.04 | 0.025 |
MACE: Major adverse cardiovascular events.
Laboratory examinations
| WBC (×109/L) | 15.16 ± 7.12 | 9.11 ± 3.20 | 0.002 |
| NEUT (×109/L) | 12.88 ± 6.88 | 6.66 ± 2.94 | 0.001 |
| Hemoglobin (g/L) | 123.36 ± 21.04 | 136.11 ± 18.03 | 0.026 |
| Platelets (×109/L) | 171.89 ± 115.79 | 208.85 ± 69.53 | 0.165 |
| ALT (U/L) | 133.50 (65.25-1584.25) | 72.00 (38.75-446.25) | 0.076 |
| BUN | 9.60 (6.36-17.00) | 5.55 (4.11-7.67) | < 0.001 |
| Creatine (μmol/L) | 109.65 (78.35-322.65) | 79.45 (66.70-87.48) | 0.003 |
| Troponin I (ng/mL) | 28.80 (8.35-87.95) | 10.30 (2.22-28.61) | 0.012 |
| Peak troponin I (ng/mL) | 34.92 (15.74-100.26) | 12.09 (2.38-48.44) | 0.014 |
| CK-MB (ng/mL) | 94.30 (31.00-122.10) | 21.40 (6.70-64.60) | 0.004 |
| Peak CK-MB (ng/mL) | 116.10 (66.10-170.60) | 22.30 (7.40-68.30) | 0.002 |
| CK (U/L) | 959.00 (307.00-1432.00) | 423.00 (149.50-710.00) | 0.044 |
| Peak CK (U/L) | 1545.00 (821.00-2067.00) | 464.00 (206.25-860.00) | 0.010 |
| D-dimer (μg/L) | 1706.00 (493.00-8608.00) | 303.00 (86.00-620.75) | 0.001 |
| Lactic acid (mmol/L) | 3.35 (2.03-6.83) | 1.45 (0.98-1.93) | < 0.001 |
MACE: Major adverse cardiovascular events; WBC: White blood cells; NEUT: Neutrophils; ALT: Alanine aminotransferase; BUN: Blood urea nitrogen; CK: Creatine kinase.
Characteristics of ultrasonic cardiogram and electrocardiograph, n (%)
| EF (%) | 35.55 ± 20.34 | 45.37 ± 11.96 | 0.062 |
| EF < 50% | 15 (75) | 21 (70) | 0.700 |
| LVEDD (mm) | 46.55 ± 4.82 | 49.07 ± 6.19 | 0.132 |
| IVST (mm) | 11.00 (8.25-12.00) | 9.00 (8.00-11.23) | 0.255 |
| ST elevation | 14 (70) | 13 (43.3) | 0.064 |
| III°AVB | 9 (45) | 11 (36.7) | 0.556 |
| QRS widen | 16 (80) | 14 (46.7) | 0.018 |
| QRS duration (ms) | 138.50 (111.75-160.25) | 111.00 (94.00-146.00) | 0.030 |
MACE: Major adverse cardiovascular events; EF: Ejection fraction; LVEDD: Left ventricular end diastolic diameter; IVST: Interventricular septal thickness; AVB: Atrioventricular block.
Treatment and intervention, n (%)
| Diuretics | 14 (70) | 22 (73.3) | 0.797 |
| Inotropic agents | 14 (70) | 9 (30) | 0.005 |
| Vasoactive agents | 20 (100) | 11 (36.7) | < 0.001 |
| Glucocorticoid | 6 (30) | 10 (33.3) | 0.804 |
| Immune globulin | 6 (30) | 8 (26.7) | 0.797 |
| Temporary pacemaker | 5 (25) | 8 (26.7) | 0.895 |
| Ventilator | 13 (65) | 1 (3.3) | < 0.001 |
| CRRT | 9 (45) | 0 (0) | < 0.001 |
| ECMO | 9 (45) | 1 (3.3) | 0.001 |
| IABP | 6 (30) | 0 (0) | 0.002 |
MACE: Major adverse cardiovascular events; CRRT: Continuous renal replacement therapy; ECMO: Extracorporeal membrane oxygenation; IABP: Intra-aortic balloon pump.
Figure 1Predictive value of baseline QRS width for major adverse cardiovascular events during hospitalization analyzed using the receive operating characteristic curve. The area under the curve was 0.683 (P = 0.030, 95%CI: 0.532-0.833). ROC: Receive operating characteristic curve.